EDIT Editas Medicine, Inc.

NASDAQ
$2.57

Editas Medicine, Inc. (EDIT) is confirmed to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is a loss of $0.21 per share.

Editas Medicine Beat Consensus Estimates
Monday, November 9, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · Before Open
Earnings Whisper
-
vs ($0.21)
Rev est $1.73M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.81

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Editas Medicine, Inc.

Editas Medicine is a development-stage genome editing biotech, which makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Though the company's discovery efforts target several disease areas, ocular diseases and engineered cell medicines are two such zones where its pipeline is most mature.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.